- Dengue vaccine CYD-TDV (Dengvaxia) vaccine
developed by Sanofi Pasteur offers hope of protection against the dreaded
- A study that
assessed the efficacy of the vaccine found that in high risk areas, the
burden of disease was lowered by 6 to 25%.
- In Low risk areas
it lead to increased hospitalization due to dengue.
A new dengue
vaccine CYD-TDV (Dengvaxia) raises hope for better
protection against the mosquito borne disease
, reducing the
burden of the disease as well as lowering medical costs in dengue prone areas.
WHO Recommends Dengue
Vaccine only for High Prone Areas
An international consortium
of dengue experts along with Stefan Flasche from the London School of Hygiene
& Tropical Medicine, UK carried out a study to understand the effectiveness
of the vaccine in lowering the burden of disease as well as price efficiency.
‘CYD-TDV (Dengvaxia) vaccine could protect children against dengue in high risk areas.’
Dynamic models that were
based on the vaccine trials as well as data on vaccinations were utilized by
the researchers to identify the impact of the vaccine and its cost
effectiveness in a variety of conditions.
to High Risk Areas for Dengue Transmission -
These are areas where at
least 50% of the children get infected with the disease. A 3 dose vaccination
schedule on at least 80% of 9 year old children would
Areas - Low Risk for Dengue Infections -
- Result in
lowering disease burden between 6 to 25%
effectiveness would be possible if the vaccines are priced competitively
out in areas where there is low risk of dengue transmission was found to be
associated with an increased risk of hospitalization due to dengue.
These findings led the
WHO to recommend the use of this vaccine in areas where there is a high risk of
dengue disease transmission.
When asked about the
significance of the study, the authors said "Our results can guide
countries on the general suitability of Dengvaxia introduction; however, local
factors related to treatment costs, intensity of dengue transmission and age
groups particularly exposed to dengue will need to be considered."
is a mosquito borne virus that is prevalent in tropical areas. It is caused by
dengue virus 1 to 4. Dengue fever is treated symptomatically and there is no known
cure or protection from the virus. Prevention is associated with controlling
the mosquito population, rather than the virus.
- Dengue fever is
associated with high body temperature and bone pain, this is why it is
also called' breakbone fever'
- 400 million
people are affected every year
- Risk of exposure
in 40% of the world population
The vaccine was
developed by Sanofi Pasteur and registered in December 2015. It has a live and
recombinant vaccine which has undergone the initial trials and will soon be
available for use, of course, the WHO recommendations need to be adhered to.
Developing a Vaccine
There are other vaccines
that are being trialed for dengue which include live attenuated vaccines and
DNA recombinant vaccines. There are 4 strains of virus that are found to cause dengue.
An infection with a particular strain of the virus provides immunity against
repeat infection of the same strain of virus. When re-infection is caused due
to another strain, there is no immunity that is generated. This highlights the
immunity associated complication in dengue. A vaccine that is developed,
therefore, should be tetravalent and offer protection against all 4 strains of
The dengue vaccine
developed by Sanofi Pasteur will offer protection against the dreaded
infection. The efficiency and cost effectiveness need to be closely monitored
to endure that this vaccine offers the best defense.
- Dengue vaccine research - (http://www.who.int/immunization/research/development/dengue_vaccines/en/)